John Leonard, Intellia CEO
Intellia plots pivotal trials for lead programs as it lays out key objectives
Intellia has some big plans for the next two years, including pivotal trials for its first two in vivo CRISPR therapies.
The Cambridge, MA-based genome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
